The National Institute for Health and Clinical Excellence has recommended nilotinib (Tasigna) for the firstline treatment of chronic myeloid leukaemia after the manufacturer agreed to reduce the price for the NHS.
In final draft guidance NICE also reaffirmed the use of imatinib (Glivec) for firstline treatment of the rare condition that affects around 560 people in the UK each year. Both drugs are made by Novartis.
A third drug, dasatinib (Sprycel), made by Bristol-Myers Squibb, was not recommended by NICE. Patients currently receiving dasatinib, however, should be able to continue treatment until they and their doctor consider it appropriate to stop.
The cost of nilotinib treatment is £31 715 (€38 100; $50 100) per year, assuming a treatment regimen of 300 mg twice a day. Novartis has agreed a patient access scheme with the Department of Health, however, which makes nilotinib available at a discounted price. The size of the discount is confidential. The standard dose of imatinib costs £20 000 per year.
Andrew Dillon, chief executive of NICE, said: "Although no trials directly comparing dasatinib and nilotinib were available, the committee concluded from indirect comparisons that dasatinib and nilotinib could be considered equally as effective in treating CML [chronic myeloid leukaemia]. The Department of Health and the manufacturer of nilotinib, however, have already agreed to provide the drug to the NHS at a discounted price."
Chronic myeloid leukaemia is a cancer of myeloid blood cells and more than 90% of people with the condition have an acquired chromosomal abnormality, the Philadelphia chromosome. The median age at diagnosis is 60 years.
A potential cure for chronic myeloid leukaemia is an allogeneic stem cell transplant, but individual characteristics and the lack of availability of a matched donor mean that this is not an option for many. Imatinib was the first of a new class of drugs that slow the progression of chronic myeloid leukaemia. After the introduction of imatinib into routine clinical practice, five year survival rate increased from 27.1% in 1990-92 to 48.7% in 2002-4. NICE guidance published in 2003 recommended standard dose imatinib (400 mg once daily) as firstline treatment for patients with Philadelphia chromosome positive chronic myeloid leukaemia in the chronic phase. The committee concluded from examining all the evidence that nilotinib and dasatinib were clinically superior to imatinib. However, the new guidance reaffirms the use of imatinib as an effective treatment for the majority of these patients and a cost effective use of NHS resources. But it also adds a further treatment option for patients by recommending nilotinib.
The committee adds that imatinib had a proven longer term record of safety and efficacy while there were only short term survival data for dasatinib and nilotinib. Cost effectiveness for both nilotinib and imatinib are similar, but should one of them become substantially cheaper it should be preferred, says NICE.
Overall the committee concluded that there was insufficient evidence to distinguish between dasatinib and nilotinib in terms of clinical effectiveness. They noted that the incremental cost effectiveness ratio for firstline nilotinib was £11 000 per quality adjusted life year gained and that it represented a cost effective firstline treatment for people with chronic phase myeloid leukaemia. However, the incremental cost effectiveness ratio for firstline treatment with dasatinib followed either by nilotinib or imatinib compared with firstline treatment with imatinib followed by nilotinib exceeded £300 000 per quality adjusted life year gained and was outside the range recommended as a cost effective use of NHS resources. Sarah Woolnough, Cancer Research UK's director of policy said, "We are pleased to see that nilotinib and imatinib have been recommended for use on the NHS. This is a great example of the pharmaceutical industry and the Department of Health working together to ensure that patients get access to drugs that will benefit them."
Duleep Allirajah, head of policy, at Macmillan Cancer Support, also welcomed the move but said they were disappointed that dasatinib had not also been recommended. "We hope that dasatinib will be put on the priority list of the government's Cancer Drugs Fund. This is based on our belief that people affected by cancer should be able to receive the treatment their doctor recommends."
In January, health secretary Andrew Lansley told parliament that the government will establish "an effective compliance regime" to ensure that primary care trusts make available all drugs that are recommended by NICE (BMJ 2012; 344:e366, doi:10.1136/bmj.e366) . "Where NICE gives a positive appraisal, a medicine should be available across the NHS," he said. 
